Select Your Region
Americas
Europa
Afrika
Weltweit
Eine Studie zur Untersuchung der Wirksamkeit von Atezolizumab bei Patient*innen mit inoperablem lokal fortgeschrittenem oder metastasierendem Urothelkarzinom der Harnwege (Announce)
A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) (Announce)
- Krebs
- Blasenkrebs
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:
Beendet
Diese Studie läuft in
Städte
- Berlin
- Braunschweig
- Bremen
- Chemnitz
- Dresden
- Eisenach
- Flensburg
- Frankfurt am Main
- Fürth
- Halle
- Halle (Saale)
- Hamburg
- Heidenheim
- Hildesheim
- Landshut
- Lebach
- Leipzig
- Luckenwalde
- Lübeck
- Lüneburg
- Mannheim
- Markkleeberg
- Minden
- München
- Naunhof
- Paderborn
- Saarbrücken
- Stade
- Trier
- Wedel
- Westerstede
Studien-ID:
NCT03399643 ML39704
Studienzusammenfassung
The objective of this study is to investigate the effectiveness of Atezolizumab with a primary focus on the overall survival (OS) rate at 2 years and secondary focuses on quality of life (QoL) and the sequence of treatment in mUC patients. Furthermore, this study aims at collecting data on safety of Atezolizumab and on the reason for cisplatin-ineligibility
Hoffmann-La Roche
Sponsor
NCT03399643,ML39704
Studien-ID
Atezolizumab
Treatments
Urothelial Carcinoma
Condition
Official Title
Non-Interventional Study To Investigate The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
Einschlusskriterien
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Metastatic UC (Urothelial Carcinoma) including cancers of the renal pelvis, ureters, urinary bladder, and urethra
- Will be receiving atezolizumab for the treatment of inoperable locally-advanced or metastatic UC, per the decision of the treating physician
- Have adequate hematologic and end-organ functions
- Have had no prior palliative chemotherapy for inoperable locally-advanced or metastatic UC and are clinically ineligible ("unfit") for cisplatin-based chemotherapy
Exclusion Criteria
- Have received prior immune checkpoint therapy
- Are pregnant or breastfeeding
- Are included in any other trial
Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de
